EN 简
EN 简

Literature Archive

Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
Presentation at ID Week 2022
Oct 21, 2022

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
Presentation at ID Week 2022
Oct 21, 2022

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-296, An Extended-Release Injectable Aqueous Suspension Formulation of Brexanolone in Healthy Adult Subjects
Presentation at the International Marcé Society Conference
Sep 19, 2022

PPD
Amubarvimab/Romlusevimab: First Approval
Drugs
Aug 23, 2022

COVID-19
Safety and Antiviral Activity of Two Monthly Administration of BRII-835 (VIR-2218), an X-Targeting RNAi Therapeutic, in Chinese Patients with Chronic HBV Infection
Presentation at the 2022 APASL conference
Mar 31, 2022

Hepatitis B
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
JHEP Reports
Sep 07, 2021

Hepatitis B
Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
medRxiv
Jul 23, 2021

COVID-19